Background
==========

Osteogenesis imperfecta (OI) is a rare monogenic disorder that shows both clinical and genetic heterogeneity. The disorder is characterized by bone fragility that varies in severity between the different OI subtypes. In the majority of patients the disorder is caused by dominant mutations in the procollagen genes *COL1A1*and *COL1A2*\[[@B1]-[@B4]\]. Even rarer than the dominant disorders are the autosomal recessive forms of OI for which several genes are known by now. These genes are mainly involved in the processing, assembly and trafficking of procollagen chains, a multi-step process that involves a large number of critical post-translational modifications. Homozygosity for mutations in *CRTAP*, *LEPRE1*, *PPIB*, or *OSTERIX*has been shown to cause mostly severe types of OI that result from overmodification of procollagen chains and their retention in the rER \[[@B2]-[@B7]\]. Autosomal recessive brittle bone disease without procollagen overmodification can be caused by mutations in either *SERPINH1*or *FKBP10*genes that encode the collagen chaperone-like proteins HSP47 and FKBP65, respectively \[[@B1],[@B3]\]. Basic pathomechanisms of OI initiated by mutations in these genes might include a failure to mature type I procollagen trimers and increased protease sensitivity \[[@B3],[@B8]\]. The pathomechanisms of another OI gene, *SERPINF1*, are still unknown \[[@B9]\]. Mutations in *FKBP10*were first described in patients with a moderate to moderate/severe form of OI type IV (OMIM 610968) \[[@B1]\]. Two follow up reports presented patients in which *FKBP10*mutations were associated with Bruck syndrome type 1, a rare disorder characterized by congenital contractures and bone fragility \[[@B10]-[@B12]\]. The question was raised if the patients in the first report indeed had isolated OI or if Bruck syndrome would have been the better diagnosis \[[@B11],[@B12]\]. We here describe three patients showing that *FKBP10*mutations not only can cause isolated OI but that the spectrum of clinical symptoms is much broader than previously described.

Methods
=======

Patients
--------

The three affected brothers, their sister and their parents provided informed consent for molecular testing, clinical assessment and the publication of their photographs. Anonymous blood samples from 80 healthy German medical students were used as controls. The experiments were performed in accordance to the Helsinki Declaration and approved by the Ethics committee of the University of Munich.

Homozygosity mapping and FKBP10 sequencing
------------------------------------------

Genomic DNA samples of family members I1-2, II1-2, and II4-5 were genotyped using the Affymetrix Axiom™ Genome-Wide Human Array, featuring 567,096 SNP markers (Affymetrix, Santa Clara, CA, USA). Extended runs of homozygosity (ROHs) shared by the three affected brothers were assessed in comparison to the unaffected family members using the program HomozygosityMapper (<http://www.homozygositymapper.org>) \[[@B13]\]. Prioritization of candidate genes within the homozygous region was performed by the program GeneDistiller (<http://www.genedistiller.org>) \[[@B14]\] and by comparison to PubMed entries (<http://www.ncbi.nlm.nih.gov/pubmed>). The complete coding sequence of the *FKBP10*gene was amplified and directly sequenced.

Results
=======

Clinical findings
-----------------

The three affected brothers, aged 46 (II1), 44 (II4), and 43 (II5) years, were born to healthy, unrelated parents. There is no family history of bone diseases or major malformations. The oldest brother was born without fractures but showed delayed motor development during his first year of life. He had his first fracture at age 9 months. The second brother was born with multiple fractures. Multiple fractures of the upper extremities at birth were also suspected in the youngest brother but not confirmed by X-ray. So far each of the brothers already had 70-100 fractures and breaks still occur. Severe progressive kyphoscoliosis has caused reduced lung capacity in all three brothers, and they are wheel-chair bound due to long bone deformities. None of the brothers showed contractures or webbing at birth. The brothers are of short stature (120-140 cm, \<3 %tile) with remarkable hypermobile joints (Figure [1](#F1){ref-type="fig"}). Relevant lab results such as alkaline phosphatase (73 U/l) are within the normal range. The primary teeth were discoloured and rapidly wore down, thus showing typical signs of dentinogenesis imperfecta (Figure [2](#F2){ref-type="fig"}). The permanent teeth are less affected. Blue sclera were noted in childhood but are no longer present.

![**Genetic studies.** A, Pedigree of the OI family. Black pedigree symbols, affected brothers, homozygous; symbols marked by black dots, unaffected family members that are heterozygous for the mutation; unmarked symbols, unaffected family members that were not available for analysis. B, Genome wide plot of Homozygosity Mapper. Red bars indicate regions with extended ROH at chromosomal regions 11q25 and 17q21.2, shared by the three affected brothers. *Homozygosity Score*threshold 0.8; HSA, *homo sapiens*chromosome. C, Sequencing results. Parts of *FKBP10*exon 7 are shown. Left side, OI patient II1 homozygous for Arg403X; right side, healthy sister (II2) heterozygous for Arg403X.](1471-2350-12-152-1){#F1}

![**Clinical phenotype**. A-B, extended left arm II1, II5. Upper arm is severely shortened in II1 and instabilized by pseudarthrosis in II5. Webbing and contractures are absent; C, joint hypermobility, demonstrated by II4; D, Radiographs of left leg and E, left side of thorax showing severe kyphoscoliosis (II4); F, Dentiogenesis imperfecta (primary teeth) in II5.](1471-2350-12-152-2){#F2}

Genetic studies
---------------

Homozygosity mapping detected two candidate ROHs in the chromosomal regions 11q25 and 17q21, respectively (Figure [1B](#F1){ref-type="fig"}). The ROH on 17q21.2 (17: 39727018-44200191, rs1010594-rs9910284, NCBI Genome Build 37.3) harbors the *FKBP10*gene encoding the FKBP65 protein (Additional File [1](#S1){ref-type="supplementary-material"}, Figure S1). Sequencing revealed a homozygous nucleotide exchange in exon 7 that changes an arginine codon into a stop codon (c.1207C\>T, FKBP65-p.(Arg403\*) (Figure [1C](#F1){ref-type="fig"}).

Discussion
==========

We identified a homozygous C-terminal premature stop codon (FKBP65-p.Arg403X) in the *FKBP10*gene causing OI in three affected siblings of a family with autosomal recessive inheritance. Both parents derived from two neighbouring small villages in Bavaria, suggesting a restricted genetic variability and a potential accumulation of recessive founder mutations in this rather isolated population. Although estimates of the relative relationship by identity-by-state allele sharing did not indicate consanguinity (see Additional File [1](#S1){ref-type="supplementary-material"}), homozygosity mapping was successfully applied to identify a causative homozygous *FKBP10*founder mutation. Our study demonstrate that homozygosity mapping represents a suitable diagnostic approach to map recessive OI genes even in outbred populations \[[@B15]\].

The first *FKBP10*mutations were found in families that were described as having OI but for which no contractures or webbing were reported \[[@B1]\]. Shaheen et al. reviewed the figures in the original publication and questioned the absence of webbing \[[@B11],[@B12]\]. Both contractures and webbing were present in their own patients as well as in all but two of the patients reported by Kelley et al.\[[@B10]\] The patients were therefore diagnosed with Bruck syndrome type 1, a distinct form of OI that is characterized by brittle bone disease and arthrogryposis multiplex congenita. Interestingly, case 2 and 4 in the report from Kelley et al. had OI but did not fulfil the criteria for Bruck syndrome \[[@B10]\]. In our family none of the three brothers had any contractures at birth or showed webbing. Thus, taken together, the previously reported patients and the family described here demonstrate that *FKBP10*can cause either Bruck syndrome or isolated OI. Additional families need to be collected to answer the question if these two clinical phenotypes are associated with specific mutations, or if isolated OI and Bruck syndrome can occur in the same family.

So far it is not known if the severity of the disorder is correlated to the position of the mutation within the *FKBP10*gene. Most patients carry frame shifting mutations that are located in the N-terminal half of the gene and are likely to cause nonsense mediated decay (NMD) (1). Interestingly, the affected brothers described here are homozygous for a C-terminal premature stop codon that, according to its vicinity to intron 7, might not initiate NMD \[[@B16],[@B17]\]. The resulting truncated protein would still have the protein-binding PPIase domains that are necessary for its chaperone function but would miss the putative rER-retention sequence (HEEL). The chaperone function might have destructive effects if exhibited outside the rER.

With the exception of some of the patients described by Alanay et al. \[[@B1]\] most previously published patients with *FKBP10*mutations had a moderate to moderate-severe form of the disorder that is best classified as OI type III. The data summarized in Table [1](#T1){ref-type="table"} show that fractures mostly started a few weeks after birth, sometimes even later, but not pre- or perinatally \[[@B1],[@B10]-[@B12]\]. Progressive skeletal deformities were rarely described. In our family at least one, but more likely two of the affected brothers were already born with multiple fractures. Subsequently, all three brothers developed extreme deformities of their long bone and spines, fulfilling the criteria for severe OI (Figure [2](#F2){ref-type="fig"}). Furthermore, dentinogenesis imperfecta was present in all three brothers but has so far not been described as a feature of patients with *FKBP10*mutations \[[@B1],[@B10]-[@B12]\]. The combination of symptoms in our family does not match the classification of OI type III but rather suggests that this family belongs to the subgroup of patients with OI type IV that show progressive skeletal deformities and dentinogenesis imperfecta.

###### 

Summary of known FKBP10 mutations

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mutations in OI and Brucks syndrome patients                                             Type                                      Position                            OI severity                                           Reference
  ---------------------------------------------------------------------------------------- ----------------------------------------- ----------------------------------- ----------------------------------------------------- -----------------------
  c.117_152del (p.Leu41GlnfsX22) homozygous                                                frame shift deletion                      upstream of 1st PPIase domain       Fractures beginning at age 3 years                    \[[@B13]\]

  c.321_353del (p.Gly107-Leu117del) homozygous                                             in frame deletion                         1st PPIase domain                   Fractures beginning in infancy                        \[[@B11]\]

  c.321_353del (p.Met107-Leu117del\*)/c.1276-\_1277insC (p.Glu426ProfsX479) heterozygous   in frame deletion/frame shift insertion   1st PPIase domain/HEEL domain       nm                                                    \[[@B13]\]

  c.344G\>A, (p.Arg115Gln)/c.831dupC (p.Gly278ArgfsX295) heterozygous                      frame shift insertion/missense mutation   1st PPIase domain/                  Fractures beginning in infancy (fist weeks of life)   \[[@B13]\]

  c.831dupC\* (p.Gly278ArgfsX295) homozygous                                               frame shift duplication                   between 2nd and 3rd PPIase domain   Fractures beginning in infancy (2 months of age)      \[[@B11]\]\
                                                                                                                                                                                                                               \[[@B13]\]

  c.1016_1023dup (p.Thr342GlyfsX26)                                                        frame shift duplication                   3^rd^PPIase domain                  Fractures beginning in infancy (7 months of age)      \[[@B14]\]

  c.1207C\>T (R403X) homozygous                                                            nonsense mutation                         HEEL domain                         Multiple fractures in fetal period                    Family presented here
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Predicted amino acid mutations are given in brackets; \*mutation nomenclature has been adapted to match the entries in the Osteogenesis Imperfecta Variant Database (<https://oi.gene.le.ac.uk>);

Conclusions
===========

Taken together, our study shows that a severe, progressive course of OI type IV with pre- or perinatal onset of fractures and dentinogenesis imperfecta has to be added to the spectrum of clinical features that can be associated with *FKBP10*mutations. We also demonstrate that homozygosity mapping represents a suitable diagnostic approach to map recessive OI genes even in outbred populations.
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